Coronary artery calcification progression and renal involvement in patients with systemic lupus erythematosus: a longitudinal cohort study.

To investigate if progression of coronary artery calcification (CAC) in patients with systemic lupus erythematosus (SLE) is associated with renal and traditional cardiovascular risk factors as well as incidence of myocardial infarctions. CAC progression was evaluated by cardiac computed tomography (CT) at baseline and after 5 years. Multivariable Poisson regression was applied to investigate associations between CAC progression and baseline values for traditional cardiovascular risk factors, CAC, SLE disease duration, lupus nephritis, and renal function.

Effects of acute hydration changes on cardiovascular magnetic resonance native T1 and T2 mapping.

Changes in hydration status may affect myocardial native T1 and T2 values and influence the clinical interpretation. We aimed to assess the impact of acute preload augmentation on native T1 and T2. Cardiovascular magnetic resonance (CMR) native T1 and T2 mapping were performed twice on the same day in 20 healthy participants before and after an acute preload augmentation by a 2-liter intravenous infusion of isotonic sodium chloride (0.

Migraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women.

Background: People with multiple sclerosis (MS) have an increased risk of migraine. However, little is known about migraine and other headaches during the prodromal phase (before MS symptom onset). Our objective was to study the risk of migraine in women with MS before MS onset.

The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.

Introduction: Ocrelizumab (OCR) is a highly effective treatment of multiple sclerosis (MS), and B cell repopulation profiles suggest that it might be used as an immune reconstitution therapy. However, data on disease recurrence after stopping treatment with OCR are scarce. Our objective was to evaluate the recurrence of disease activity after OCR discontinuation.

Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients.

Background: Patients with multiple sclerosis (MS) treated with anti-CD20 therapies such as rituximab may have increased risk of severe COVID-19 disease. Vaccination induces protective immunity, but humoral vaccine response is known to be attenuated in rituximab-treated MS-patients-patients, which has indicated a need for real world data on severe morbidity and mortality from COVID-19 after vaccination.

Methods: Rituximab-treated patients treated at Haukeland University Hospital were identified through the National MS Registry and invited to participate in the study by giving a consent and providing a blood sample 3 weeks or later after ordinary COVID-19- vaccination, i.